Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.45 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.44 |
| ▸ | C5AR1 | P21730 | 1/20 | 0.43 |
| ▸ | MKNK1 | Q9BUB5 | 6/20 | 0.43 |
| ▸ | F12 | P00748 | 1/20 | 0.43 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.42 |
| ▸ | GRM5 | P41594 | 2/20 | 0.41 |
| ▸ | PARP1 | P09874 | 1/20 | 0.41 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.41 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.41 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.40 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31548527 | 0.87 | ESR2 (0.48) | MAPTESR2NR1H2C5AR1MKNK1 | |
| SCHEMBL1329919 | 0.87 | ESR2 (0.48) | MAPTESR2NR1H2C5AR1MKNK1 | |
| SCHEMBL1330087 | 0.86 | ESR2 (0.47) | MAPTESR2NR1H2C5AR1MKNK1 | |
| SCHEMBL12305710 | 0.84 | MAPT (0.45) | MAPTESR2NR1H2C5AR1MKNK1 | |
| SCHEMBL17804469 | 0.80 | NOTUM (0.41) | MAPTGRM5 | |
| SCHEMBL1017552 | 0.80 | POLB (0.43) | MAPTESR2NR1H2MKNK1ADORA1 | |
| SCHEMBL22715947 | 0.80 | ESR2 (0.43) | MAPTESR2NR1H2MKNK1ADORA1 | |
| SCHEMBL9951760 | 0.79 | ESR2 (0.48) | MAPTESR2NR1H2MKNK1ADORA1 | |
| SCHEMBL1013846 | 0.79 | POLB (0.48) | MAPTESR2MKNK1ADORA1GPR119 | |
| SCHEMBL2511081 | 0.79 | POLB (0.43) | MAPTESR2NR1H2MKNK1ADORA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8022222-B2 | Glucokinase activators | ARRAY BIOPHARMA, INC. (US) | 2011-09-20 | — | — | US | disclosed |
| US-20090247526-A1 | GLUCOKINASE ACTIVATORS | ARRAY BIOPHARMA INC. (US) | 2009-10-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090247526-A1 | GLUCOKINASE ACTIVATORS | GCKR, GCK, GALK1 | MAPT 4375/4885ESR2 1352/4885NR1H2 611/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.